Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Equillium, Inc. (EQ) vs Genelux Corporation (GNLX)

Equillium, Inc. and Genelux Corporation are both Biotechnology companies. Equillium, Inc. and Genelux Corporation are of similar size ($110.0M and $109.1M). Across the 11 metrics below, Equillium, Inc. leads on 9 and Genelux Corporation on 2.

Valuation

Metric EQ GNLX Biotechnology median
P/E n/m n/m 7.88
P/S 4.54 9.91 11.47
P/B 3.33 6.92 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 3.18 8.37 10.73
Earnings yield (11.98%) (34.68%) (28.84%)
Free cash flow yield (10.75%) (25.73%) (23.03%)

Profitability

Metric EQ GNLX Biotechnology median
Gross margin 100.00% (3.42%) 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (58.98%) (177.93%) (57.72%)
Return on assets (50.68%) (121.80%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric EQ GNLX Biotechnology median
Revenue growth (TTM) 13.89% — 5.64%
EPS growth (last fiscal year) (69.57%) 9.47% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric EQ GNLX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 23.40 2.39 4.73
Net debt to EBITDA 1.29 0.44 0.96

Dividend

Metric EQ GNLX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric EQ GNLX Biotechnology median
Market cap 109.06m 109.95m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack